Anti-PD-1 treatment responses in NSCLC are also noted if tumor tissues lack PD-L1 expression, and our present and other recent studies have confirmed that PD-L1 expression is higher in CTCs than in tumor tissue [31,32]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.